BioCentury
ARTICLE | Product Development

A more excellent choice

February 23, 2009 8:00 AM UTC

Arete Therapeutics Inc. decided to switch gears and focus on developing its first-in-class oral soluble epoxide hydrolase inhibitor for Type II diabetes rather than hypertension based on a more robust antidiabetic profile in preclinical models. If the company succeeds, it could have a drug that controls glucose while providing renal and cardioprotection.

The company began a 28-day Phase IIa trial of AR9281 in 150 patients with impaired glucose tolerance and high blood pressure earlier this month to provide the company with an idea about the ability of twice-daily AR9281 to modulate glucose metabolism and blood pressure...